In vitro vaccine challenge of PBMCs from BNT162b2 anaphylaxis patients reveals HSP90α-NOD2-NLRP3 nexus

Allergy. 2023 Jan;78(1):304-307. doi: 10.1111/all.15503. Epub 2022 Sep 10.

Hui Ling Ko¹, Nicole Zhuo¹, Zi Wei Chang², Anindita Santosa^{3

4}, Shirin Kalimuddin^{4

5}, Xin Rong Lim⁶, Seow Yen Tan³, David Chien Lye^{6

7

8

9}, Dorothy Toh¹⁰, Barnaby Edward Young^{6

7

8}, Laurent Renia^{2

8

11}, Haur Yueh Lee⁵, Ee Chee Ren^{1

12}

¹ Singapore Immunology Network, A*STAR, Singapore, Singapore.
² A*STAR Infectious Diseases Labs, A*STAR, Singapore, Singapore.
³ Changi General Hospital, Singapore, Singapore.
⁴ Duke-NUS Medical School, Singapore, Singapore.
⁵ Singapore General Hospital, Singapore, Singapore.
⁶ Tan Tock Seng Hospital, Singapore, Singapore.
⁷ National Centre for Infectious Diseases, Singapore, Singapore.
⁸ Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
⁹ Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
¹⁰ Health Sciences Authority, Singapore, Singapore.
¹¹ School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
¹² Department of Microbiology & Immunology, National University of Singapore, Singapore, Singapore.

No abstract available

Keywords: COVID-19 mRNA vaccine; HSP90α; NLRP3 inflammasome; NOD2; anaphylaxis.

Publication types